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Introduction: The association between anaphylactic reactions and systemic mastocytosis is well documented.
However, platelet transfusion has not previously been reported as a potential elicitor of anaphylaxis in the context
of systemic mastocytosis.
Case presentation: We describe the clinicopathological findings of a 59-year-old Latin American man who presented
to the emergency room with fatigue, leukocytosis, thrombocytopenia and mild hepatosplenomegaly. He developed
two separate, temporally associated and severe anaphylactic reactions after receiving platelet transfusions. The result of
a laboratory investigation for clerical errors and Coombs test was negative. Pre- and post-transfusion urine samples
were negative for hemolysis. Bone marrow biopsy and aspirate smears performed demonstrated involvement by
systemic mastocytosis, which had been previously undiagnosed.
Conclusions: We posit the transfusion reaction to be an anaphylactic reaction to transfused products as a result of
heightened allergic sensitivity due to the underlying systemic mastocytosis. To the best of our knowledge, this is the
first reported case of a severe anaphylactic-type reaction to blood products occurring in the setting of a previously
undiagnosed systemic mastocytosis. Furthermore, it seems there are no published studies closely examining the
relationship between hematopoietic neoplasms and transfusion reactions in general.
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Mast cells were first described by Paul Erlich in 1878
and play an important role in allergy, anaphylaxis, and
defense against pathogens. These cells have abundant
cytoplasmic granules which are composed predomi-
nantly of heparin and histamine [1]. Normal degranula-
tion of mast cells occurs via antigen-immunoglobulin
(Ig) E complex-mediated binding to membrane-bound
FcεRI (high-affinity IgE) receptors which in turn release* Correspondence: cblieden@gmail.com
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unless otherwise stated.histamine and heparin-rich granules into the circula-
tion [1].
Non-IgE-mediated mechanisms of mast cell degranula-
tion can also occur. These include predominantly physical
stimuli such as cold temperature, radiation, ethanol, exer-
cise, and friction in addition to several exogenous sub-
stances such as medication, radio-contrast media and
venom [2]. Several blood-derived substances may also ini-
tiate the process of mast cell degranulation, including im-
mune aggregates, Igs, platelets and T cells [2].
Anaphylaxis is the result of massive mast cell ac-
tivation and degranulation and is a serious and life-
threatening allergic reaction that occurs with rapid onset
[2]. Symptoms include but are not limited to hives, an-
gioedema, wheezing, and hypotension with tachycardia.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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chemical exposures among other things. However, etio-
logic agents are frequently difficult to identify in clinical
practices. The estimated prevalence of people having
had at least one anaphylactic reaction is 0.5 to 2% and is
thought to be increasing [3].
Systemic mastocytosis (SM) is part of a spectrum of
diseases which are characterized by the proliferation of
neoplastic mast cells [4]. Clinical symptoms of SM vary
in severity and can occur over a broad range of organ
systems, making the clinical diagnosis difficult. Common
symptoms include constitutional symptoms, skin mani-
festations, and musculoskeletal symptoms all of which
are termed “mast cell mediator-related systemic symp-
toms”. SM tends to present after the second decade of
life, whereas the more common cutaneous mastocytosis
has a predilection towards pediatric populations [4].
Clinical management of mastocytosis ranges from pallia-
tive means in mild cases to cladribine in more severe
cases. SM can be associated with KIT mutations. In fact,
imatinib has a role in severe diseases with KIT gene mu-
tation, particularly in those with associated clonal mye-
loid neoplasms. Furthermore, KIT mutations confer a
resistance to imatinib therapy and a poorer prognosis in
severe cases [5].
Anaphylaxis is included in the category of mast cell
mediator-related symptoms and is not uncommonly
seen in patients with SM [6-8]. A recent Swedish study
of 84 adult patients with SM revealed that 36% of these
patients had at least one episode of anaphylaxis [9]. An
American study of 120 adult and pediatric patients
found a 49% incidence of anaphylaxis in patients with
SM [10]. As is commonly the case in other patients with
anaphylaxis, a causative trigger was not identified in the
majority of these cases.
We here present a case of SM which was diagnosed
after two sequential episodes of anaphylaxis, each occur-
ring with platelet transfusion as the precipitating event.
This report serves as a reminder to clinicians of the
possibility of an underlying SM in the settings of an ana-
phylactic reaction to blood products as well as the
clinical implications of the use of transfused blood pro-
ducts in such patients. Finally, this study highlights the
need for further studies investigating the association
between transfusion reactions and hematopoietic neo-
plasms in general, a virtually unexplored topic of clinical
interest.
Case presentation
A 59-year-old Latin American man with a reported his-
tory of atrial fibrillation presented to the emergency
room with fatigue, progressive abdominal pain, and
weight loss. Significant laboratory findings were elevated
white blood count (37×103/μL) with markedly increasedeosinophilia (46% of manual leukocyte differential cell
count) and thrombocytopenia (17×103/μL). Hemoglobin
was 11.5g/dL and hematocrit was 34.3%. His physical
examination was notable for mild hepatosplenomegaly.
An initial bone marrow biopsy performed was non-
diagnostic due to inadequate material.
He was admitted for unexplained leukocytosis and
thrombocytopenia. On admission, he received single
donor platelet transfusion. This was performed in part
because despite the lack of active bleeding, he had areas
of petechiae on the upper extremities and hard palate
and gave a reported history of melena. Almost immedi-
ately after initiation of platelet transfusion (per nursing
notes less than 10 minutes after beginning transfusion)
he developed hypotension (blood pressure 77/40mmHg),
diaphoresis, respiratory distress, and atrial fibrillation
with rapid ventricular response (heart rate 200 beats per
minute). He was urgently treated with amiodarone,
metoprolol, intravenous diphenhydramine, and 1500mL
normal saline bolus. He did not have urticarial symp-
toms, nor did he report wheezing per se, however, he
did complain of shortness of breath. Mild pulmonary
edema was noticed on the subsequent chest X-ray; how-
ever, this study was not performed in the immediate
post-episodic interval, and in fact was performed 6.5
hours after the episode. No fever occurred. He had not
been taking angiotensin-converting enzyme inhibitors.
Cardiac enzymes were negative at the time and remained
negative in the days following the episode. Brain na-
triuretic peptide levels were not ordered. With prompt
medical attention, he was quickly stabilized and subse-
quently transferred to the intensive care unit.
The transfusion medicine service was consulted for in-
vestigation of the cause of the transfusion reaction and
guidance for the safety of future blood product transfu-
sions. Clerical errors were ruled out by standard labora-
tory protocol. Both direct and indirect Coombs tests
were negative. Pre- and post-transfusion urine samples
did not demonstrate hemolysis. The initial interpretation
was that the symptoms were possibly the result of either
a transfusion-related acute lung injury (TRALI) or an
anaphylactic reaction. The lack of urticarial symptoms
made for ambiguity in diagnosing an anaphylactic re-
action; however, the loss of hemodynamic stability,
possibility due to vasodilation, kept anaphylaxis in the
differential. TRALI was a consideration because he had
complained of shortness of breath. The lack of an imme-
diate post-interval chest X-ray confounded the exclusion
of TRALI, which has a characteristic marked transient
pulmonary edema. Although the etiology of the reaction
was unclear at this point, a TRALI was favored over an
allergic-type anaphylactic reaction. Concurrently, a bone
marrow biopsy had been performed but was unsatisfac-
tory and thus non-diagnostic.
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With the diagnosis of an allergic-type reaction not fully
elucidated, and the diagnosis of SM not yet made or
even suspected, another platelet transfusion with close
medical attention was attempted for the same clinical
reasons at presentation. An almost identical reaction oc-
curred. This time, he had received pretreatment with
intravenous diphenhydramine and Solu-Medrol® (meth-
ylprednisolone sodium succinate). Within a short period
of time after initiation of platelet transfusion (approxi-
mately 15 minutes after initiation of transfusion), he expe-
rienced shortness of breath, hypotension (blood pressure
73/42mmHg), and symptomatic cardiac arrhythmias. Iden-
tical medical interventions using antiarrhythmics, beta-
blockers, and antihistamines were again implemented. He
responded quickly to medical intervention and was sub-
sequently again transferred to the intensive care unit. A
second bone marrow examination was performed and a
diagnosis of SM was made.
Peripheral blood demonstrated a leukocytosis with sig-
nificant eosinophilia, with 49% of nucleated cells being
eosinophils. All leukocytes were morphologically unre-
markable. Circulating blasts were not seen. His bone
marrow examination was significant for hypercellularity
with marked spindle cell proliferation constituting ap-
proximately 90% of the marrow cellularity. Bone marrowFigure 1 Bone marrow involvement by mastocytosis. A. The bone mar
proliferation of spindle cells admixed with small lymphocytes and eosinoph
core biopsy demonstrating marked spindle cell morphology. C. Clusters of
smears. D. The neoplastic mast cells were positive for CD117 and CD25 (shaspirate had few particles; however, cellular material
present consisted predominantly of clustered mast cells
(Figures 1A to 1C). Immunohistochemical studies demon-
strated spindle cells to be positive for CD25 (Figure 1D) in
addition to CD2, CD117, and tryptase. Based on these
findings, a diagnosis of SM was made. Molecular studies
showed a KIT gene mutation D816V by polymerase chain
reaction. Results from serum tryptase levels collected after
the first episode were made available to the clinicians and
were found to be abnormally elevated (>200ng/mL; refer-
ence range 5 to 10ng/mL). Ig levels performed after trans-
fusion were essentially normal for IgG, IgA, and IgE. IgM
was found to be slightly elevated (234mg/dL; reference
range 40 to 230mg/dL). He was unsure about his prior
transfusion history, and records from outside institutions
were unavailable. This patient was lost to follow up for
clinical purposes, however our institution was notified
of his death approximately 4 months after his initial
diagnosis.
Because of the unlikelihood of having two successive
TRALI reactions in addition to the confirmed diagnosis
of SM, the etiology of the transfusion reactions was
thought to be a result of induced mast cell hypersensi-
tivity; either by the platelets themselves (i.e. membrane
phospholipids), concentrated platelet derived substances
contained in the transfused units (serotonin, histamine,row core biopsy is hypercellular (90%) due to the presence of a
ils. B. High power image of mast cell aggregates in bone marrow
hypogranular mast cells were seen in the bone marrow aspirate
own).
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action to another attempted platelet transfusion from a
different donor virtually excluded TRALI as a possibility.
Conclusions
Based on clinical grounds and pathological findings, we
infer that the most likely etiology of this patient’s trans-
fusion reaction was anaphylactic reaction as a result of
hypersensitivity due to SM. Because of this diagnosis,
the clinical team opted to manage the patient such that
future transfusions would be performed conservatively
in acute care settings, with washed blood products, and
using pretreatment with corticosteroids and antihista-
mines. As in all allergic-type reactions, IgA was con-
sidered a possibility; however, studies collected on the
patient after attempted transfusion were within normal
limits. We acknowledge that, in general, transfusion may
alter IgA levels and give a falsely normal reading. This is
a more common phenomenon in plasma transfusion
[11]. Considering that the product transfused was plate-
lets as opposed to plasma, and that such a limited
amount was transfused, our impression is that the mea-
sured normal IgA levels were probably not altered by
the transfused platelets and that the laboratory and cli-
nical findings did not support the diagnosis of IgA
deficiency.
Anaphylactic reactions are a known entity among
transfusion reactions, with an incidence of approxi-
mately 1:20,000 to 1:50,000 [11]. Symptoms are not
unlike anaphylactic symptoms in other circumstances
and may include hypotension, tachycardia, respiratory
difficulty, urticaria, and other allergic-type symptoms.
Patients who have an anaphylactic reaction to transfused
blood products are subsequently managed with washed
blood products as needed in addition to pretreatment
with antihistamines and corticosteroids as deemed ne-
cessary. The clinical team was counseled in this regard
and urged only to transfuse with acute care immediately
available. The clinical team never again attempted trans-
fusion over the course of this patient’s hospitalization. A
common cause for anaphylactic reaction is transfusion
of products to patients with IgA deficiency, who sub-
sequently react to the foreign IgA antigen in the donor
unit [11]. As previously mentioned, this patient had nor-
mal serum IgA levels. He was subsequently lost to follow
up and his clinical course after discharge remains
unknown.
It is not uncommon for transfusion reactions to be dif-
ficult to classify as many do not fit perfectly into the cri-
teria established for various entities. This is particularly
true when TRALI is included in the differential as was
initially the case in this scenario. The reported incidence
of TRALI ranges from 1:1200 to 1:190,000 [11]. This
variance may be because of the frequent difficulty inidentifying an unequivocal TRALI. The mechanism of
TRALI is thought to be due to human leukocyte antigen
(HLA) antibodies of the donor unit directed against the
recipient, which classically manifests as a dramatic tran-
sient pulmonary edema shortly after transfusion [11].
Blood units with a higher incidence of HLA-associated
donor-related antibodies, which increase the risk of
TRALI, have been found to have an increased incidence
in multiparous female donors [11].
In this particular case, the chest X-ray was not taken in
the immediately post-episodic period, and hence the fin-
dings of minimal pulmonary edema confounded the po-
tential exclusion of TRALI as a cause of this patient’s
symptoms. Cardiac symptoms are not included in the def-
inition of TRALI. This patient’s history of cardiac disease
further confounded the exclusion of TRALI diagnosis and
also made for difficulty in attributing the hypotension to
anaphylaxis. That is to say, it was thought that an exacer-
bation of the pre-existing cardiac disease by a suspected
TRALI might have given rise to the hypotension. The fact
that he had the exact reaction to another platelet transfu-
sion virtually excluded TRALI as a possibility. Further-
more, the subsequent bone marrow findings identifying
an undiagnosed mastocytosis led to the conclusion that
the most likely etiology of this patient’s reaction was ana-
phylactic hypersensitivity.
The association of an anaphylactic reaction to platelet
transfusion arising in the setting of an underlying SM, as
seen in this case, has not previously been reported in the
literature (PubMed). In fact, it appears that the relation-
ship between transfusion reactions and hematopoietic
neoplasms as a whole has yet to be explored as a topic
of clinical interest. As previously mentioned, the clinical
manifestations of mastocytosis are broad ranging. This
in combination with the fact that the disease is a rela-
tively uncommon entity makes the diagnosis easily
missed by clinicians.
We suspect that the mechanism of reactions seen in
this case is part of a mast cell activation syndrome oc-
curring in the setting of SM [6]. It is possible that this
was an IgE-mediated allergic reaction and subsequent
massive mast cell degranulation, although this seems un-
likely given that he had normal IgE levels. Another pos-
sible mechanism is the massive activation of neoplastic
mast cells by leukocyte or platelet-derived substances
contained in the transfused units. Some possible candi-
dates include platelet-activating factor (PAF) and stem
cell factor (SCF). Both PAF and SCF are found in signifi-
cant amounts in transfused platelets. Notably, PAF has
been implicated in the development of anaphylactic re-
actions via histamine release [7]. Also, SCF is known to
not only stimulate proliferation of mast cells via c-kit
but also to be a potent mast cell agonist leading to his-
tamine release [12-14]. It might also be true that the
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played a role in this patient’s adverse reaction due to in-
creased susceptibility to other activating stimuli; how-
ever, this is only conjecture. In any regard, the exact
mechanism of mast cell activation cannot be determined
with certainty in this case. Understanding the exact
mechanism of anaphylaxis would require an experimen-
tal study involving an animal model.
Further identification and understanding of the asso-
ciation between SM and potential anaphylactic-type
transfusion reactions is important because the awareness
of this association may allow for more optimal manage-
ment in patients with SM. Specifically, clinicians should
be aware that patients with SM who require transfusion
of blood products may require pretreatment with anti-
histamines and corticosteroids. This is an important
topic of consideration because the physiological burden
of SM in the marrow leads to marrow suppression and
subsequent need for transfusion. Furthermore, this case
serves as an example of the need for investigation of the
potential correlation between hematopoietic neoplasms
and transfusion reactions. Although this topic has yet to
be explored, the connection between the two entities
seems intuitively possible. Because of the complications
that may arise with transfusion of blood products, one
would think that such research could be of great clinical
importance as patients with hematopoietic neoplasms
are likely to require blood product transfusions over the
course of their disease.Consent
Institutional Review Board approval (IRB 20140281) was
received for this manuscript as we were unable to con-
tact the deceased patient’s next of kin for consent to
publish despite all reasonable attempts. All efforts were
made to keep our deceased patient's identity anonymous
and there is no reason to believe that our patient would
have objected to publication of this case report.
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